Drug Profile
ASP 1001
Alternative Names: ASP-1001Latest Information Update: 01 Dec 2017
Price :
$50
*
At a glance
- Originator Asphelia Pharmaceuticals
- Class Antiallergics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Allergic rhinitis
Most Recent Events
- 01 Dec 2017 Discontinued - Phase-II/III for Allergic rhinitis in USA (Intranasal)